These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

349 related articles for article (PubMed ID: 25931832)

  • 1. Management of acute attacks of hereditary angioedema: role of ecallantide.
    Duffey H; Firszt R
    J Blood Med; 2015; 6():115-23. PubMed ID: 25931832
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Ecallantide for the treatment of hereditary angiodema in adults.
    Lunn M; Banta E
    Clin Med Insights Cardiol; 2011; 5():49-54. PubMed ID: 21695090
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Critical role of kallikrein in hereditary angioedema pathogenesis: a clinical trial of ecallantide, a novel kallikrein inhibitor.
    Schneider L; Lumry W; Vegh A; Williams AH; Schmalbach T
    J Allergy Clin Immunol; 2007 Aug; 120(2):416-22. PubMed ID: 17559913
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Ecallantide for treatment of acute hereditary angioedema attacks: analysis of efficacy by patient characteristics.
    MacGinnitie AJ; Campion M; Stolz LE; Pullman WE
    Allergy Asthma Proc; 2012; 33(2):178-85. PubMed ID: 22525395
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Ecallantide: a plasma kallikrein inhibitor for the treatment of acute attacks of hereditary angioedema.
    Stolz LE; Horn PT
    Drugs Today (Barc); 2010 Aug; 46(8):547-55. PubMed ID: 20830315
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Use of ecallantide in pediatric hereditary angioedema.
    MacGinnitie AJ; Davis-Lorton M; Stolz LE; Tachdjian R
    Pediatrics; 2013 Aug; 132(2):e490-7. PubMed ID: 23878046
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Ecallantide for treatment of acute attacks of hereditary angioedema.
    Martello JL; Woytowish MR; Chambers H
    Am J Health Syst Pharm; 2012 Apr; 69(8):651-7. PubMed ID: 22472866
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Prospective, double-blind, placebo-controlled trials of ecallantide for acute attacks of hereditary angioedema.
    Stolz LE; Sheffer AL
    Expert Rev Clin Immunol; 2012 Jan; 8(1):25-32. PubMed ID: 22149337
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Treatment of hereditary angioedema-single or multiple pathways to the rescue.
    Valerieva A; Longhurst HJ
    Front Allergy; 2022; 3():952233. PubMed ID: 36172291
    [TBL] [Abstract][Full Text] [Related]  

  • 10. EDEMA4: a phase 3, double-blind study of subcutaneous ecallantide treatment for acute attacks of hereditary angioedema.
    Levy RJ; Lumry WR; McNeil DL; Li HH; Campion M; Horn PT; Pullman WE
    Ann Allergy Asthma Immunol; 2010 Jun; 104(6):523-9. PubMed ID: 20568386
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Outcomes after ecallantide treatment of laryngeal hereditary angioedema attacks.
    Sheffer AL; MacGinnitie AJ; Campion M; Stolz LE; Pullman WE
    Ann Allergy Asthma Immunol; 2013 Mar; 110(3):184-188.e2. PubMed ID: 23548529
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Ecallantide: in acute hereditary angioedema.
    Garnock-Jones KP
    Drugs; 2010 Jul; 70(11):1423-31. PubMed ID: 20614949
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Response to ecallantide treatment of acute attacks of hereditary angioedema based on time to intervention: results from the EDEMA clinical trials.
    Banta E; Horn P; Craig TJ
    Allergy Asthma Proc; 2011; 32(4):319-24. PubMed ID: 21781409
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Analysis of hereditary angioedema attacks requiring a second dose of ecallantide.
    Li HH; Campion M; Craig TJ; Soteres DF; Riedl M; Lumry WR; MacGinnitie AJ; Shea EP; Bernstein JA
    Ann Allergy Asthma Immunol; 2013 Mar; 110(3):168-72. PubMed ID: 23548526
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Hereditary angioedema in childhood: an approach to management.
    Ebo DG; Verweij MM; De Knop KJ; Hagendorens MM; Bridts CH; De Clerck LS; Stevens WJ
    Paediatr Drugs; 2010 Aug; 12(4):257-68. PubMed ID: 20593909
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Assessment of rebound and relapse following ecallantide treatment for acute attacks of hereditary angioedema.
    Bernstein JA; Shea EP; Koester J; Iarrobino R; Pullman WE
    Allergy; 2012 Sep; 67(9):1173-80. PubMed ID: 22765833
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Ecallantide is a novel treatment for attacks of hereditary angioedema due to C1 inhibitor deficiency.
    Farkas H; Varga L
    Clin Cosmet Investig Dermatol; 2011; 4():61-8. PubMed ID: 21760740
    [TBL] [Abstract][Full Text] [Related]  

  • 18. New therapies for hereditary angioedema: disease outlook changes dramatically.
    Frank MM; Jiang H
    J Allergy Clin Immunol; 2008 Jan; 121(1):272-80. PubMed ID: 18206518
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Ecallantide for treatment of acute attacks of acquired C1 esterase inhibitor deficiency.
    Patel NS; Fung SM; Zanichelli A; Cicardi M; Cohn JR
    Allergy Asthma Proc; 2013; 34(1):72-7. PubMed ID: 23406939
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Abdominal attacks and treatment in hereditary angioedema with C1-inhibitor deficiency.
    Rubinstein E; Stolz LE; Sheffer AL; Stevens C; Bousvaros A
    BMC Gastroenterol; 2014 Apr; 14():71. PubMed ID: 24712435
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 18.